Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects

Current Medical Research and Opinion

Volumn 27, Issue 12, 2011, Pages 2261-2270

  Mizuyachi, Kaori ^a   Hara, Katsutoshi ^a   Wakamatsu, Akira ^a   Nohda, Shigeru ^a   Hirama, Toshiyasu ^a  

^a Japan Development and Medical Affairs Division   (Japan)

Author keywords

Colistin methanesulfonate; Healthy volunteer; Intravenous; Pharmacokinetics; Safety

Indexed keywords

BETA 2 MICROGLOBULIN; COLISTIMETHATE; N ACETYL BETA GLUCOSAMINIDASE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BETA 2 MICROGLOBULIN URINE LEVEL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; GAIT DISORDER; HUMAN; HUMAN EXPERIMENT; JAPANESE; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NORMAL HUMAN; ORAL PARESTHESIA; PLASMA CONCENTRATION-TIME CURVE; PROTEIN URINE LEVEL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; VOMITING;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COLISTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; HUMANS; INFUSIONS, INTRAVENTRICULAR; JAPAN; MALE; MICE; MIDDLE AGED;

EID: 81855225303     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.626557     Document Type: Article

References (23)

1. Arnold TM, Forrest GN, Messmer KJ. Polymyxin antibiotics for gram-negative infections. Am J Health Syst Pharm 2007;64:819-26
2. Falagas ME, Kasiakou SK, Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4:138-46
3. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601
4. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22:535-43
5. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005a;40:1333-41
6. Bergen PJ, Li J, Rayner CR, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-8
7. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust 1970;2:923-4
8. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68
9. Ryan KJ, Schainuck LI, Hickman RO, et al. Colistimethate toxicity. Report of a fatal case in a previously healthy child. JAMA 1969;207: 2099-101
10. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005b;5:1
11. Couet W, Grégoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011;89:875-9
12. Gobin P, Lema?̂tre F, Marchand S, et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010;54:1941-8
13. World Medical Association. Declaration of Helsinki - ethical principles for medical research involving human subjects. 2008
14. Coly-Mycin M Parenteral Package Insert, 2007
15. Li J, Milne RW, Nation RL, et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by highperformance liquid chromatography. Antimicrob Agents Chemother 2003a; 47:1364-70
16. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
17. Jansson B, Karvanen M, Cars O, et al. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal 2009;49:760-7
18. Galani I, Kontopidou F, Souli M, et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008;31:434-9
19. Dudhani RV, Li J, Nation RL. Plasma binding (PB) of colistin involves multiple proteins and is concentration dependent: potential clinical implications. 2009, 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, USA
20. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/ pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010;54:1117-24
21. Etherington C, Bosomworth M, Clifton I, et al. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J Cyst Fibros 2007;6:67-73
22. Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992;38:S14-19
23. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94